Spots Global Cancer Trial Database for aldesleukin
Every month we try and update this database with for aldesleukin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03691376 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim... | Aldesleukin Autologous NY-E... Cellular Therap... Melphalan | 18 Years - | Roswell Park Cancer Institute | |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | NCT01823198 | Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related... | Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological... | 7 Years - 65 Years | M.D. Anderson Cancer Center | |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | NCT02757391 | Colorectal Aden... Metastatic Chol... Metastatic Colo... Metastatic Dige... Metastatic Esop... Metastatic Gast... Metastatic Panc... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Adoptive Immuno... Aldesleukin Cyclophosphamid... Laboratory Biom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer | NCT00002846 | Kidney Cancer | aldesleukin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT00005038 | Kidney Cancer | aldesleukin histamine dihyd... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | NCT01640301 | Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ... | - | Fred Hutchinson Cancer Center | |
| Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00045149 | Melanoma (Skin) | aldesleukin therapeutic tum... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | NCT00004128 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 | NCT03233828 | Melanoma (Skin) Melanoma in Sit... | Aldesleukin Saline | 18 Years - 80 Years | Nova Scotia Health Authority | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma | NCT00020462 | Lymphoma | aldesleukin autologous tumo... | 18 Years - | National Cancer Institute (NCI) | |
| High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | NCT01266603 | Melanoma | HDIL-2 recMAGE-A3 + AS... | 18 Years - | M.D. Anderson Cancer Center | |
| Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | NCT00002649 | Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... | aldesleukin filgrastim cyclophosphamid... etoposide radiation thera... peripheral bloo... bone marrow abl... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00002669 | Melanoma (Skin) | aldesleukin recombinant int... cisplatin dacarbazine | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | NCT00665470 | Skin Cancer Metastatic Mela... | Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor | NCT04862767 | Solid Tumor | TASO-001((TGF-β... Aldesleukin | 19 Years - | Autotelicbio | |
| T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | NCT02280811 | Vaginal Cancer Cervical Cancer Anal Cancer Penile Cancer Oropharyngeal C... | Fludarabine Cyclophosphamid... E6 TCR Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | NCT00062036 | Melanoma (Skin) | aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00004025 | Melanoma (Skin) | aldesleukin dendritic cell-... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00019994 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | NCT04426669 | Gastrointestina... Gastrointestina... Cancer of Gastr... Cancer, Gastroi... Gastrointestina... Colo-rectal Can... Pancreatic Canc... Gall Bladder Ca... Colon Cancer Esophageal Canc... Stomach Cancer | Cyclophosphamid... Fludarabine Tumor-Infiltrat... Aldesleukin | 18 Years - 70 Years | Intima Bioscience, Inc. | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma | NCT00054405 | Recurrent Neuro... | recombinant int... aldesleukin | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation | NCT00003743 | Neuroblastoma | aldesleukin | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | NCT01754376 | Melanoma | Aldesleukin Vemurafenib | 18 Years - | Massachusetts General Hospital | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | NCT00008190 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo... | - | National Cancer Institute (NCI) | |
| Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery | NCT00003604 | Kidney Cancer | aldesleukin | - | National Cancer Institute (NCI) | |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent | NCT02470559 | Malignant Ovari... Malignant Ovari... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Aldesleukin HER2Bi-Armed Ac... Laboratory Biom... Sargramostim | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | NCT00022230 | Breast Cancer | aldesleukin filgrastim sargramostim therapeutic aut... cyclophosphamid... doxorubicin hyd... paclitaxel | 18 Years - | Roger Williams Medical Center | |
| Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer | NCT00053807 | Kidney Cancer | aldesleukin recombinant int... fluorouracil adjuvant therap... | - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma | NCT00003091 | Kidney Cancer Melanoma (Skin) | aldesleukin recombinant int... | 18 Years - | Hoag Memorial Hospital Presbyterian | |
| Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer | NCT00003090 | Lung Cancer | aldesleukin | - | National Cancer Institute (NCI) | |
| Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | NCT01700946 | Recurrent B-Cel... Recurrent Child... | dexamethasone vincristine sul... rituximab clofarabine cyclophosphamid... etoposide aldesleukin pegaspargase methotrexate mercaptopurine cytarabine mitoxantrone teniposide vinblastine natural killer ... laboratory biom... therapeutic hyd... allogeneic hema... CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05267626 | Advanced Solid ... Metastatic Canc... | AU-007 Aldesleukin | 18 Years - | Aulos Bioscience, Inc. | |
| Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | NCT00006244 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | melphalan recombinant int... aldesleukin in vitro-treate... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | NCT00003356 | Lymphoma | aldesleukin rituximab | 18 Years - 75 Years | University of Rochester | |
| High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2 | NCT00080977 | Kidney Cancer | aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | NCT03449108 | Bone Sarcoma Dedifferentiate... Giant Cell Tumo... Malignancy in G... Malignant Solid... Ovarian Carcino... Platinum-Resist... Poorly Differen... Recurrent Osteo... Recurrent Ovari... Refractory Oste... Soft Tissue Sar... Thyroid Gland A... Thyroid Gland S... Undifferentiate... Triple Negative... | Aldesleukin Autologous Tumo... Autologous Tumo... Cyclophosphamid... Fludarabine Ipilimumab Nivolumab Quality-of-Life... Questionnaire A... | 16 Years - 70 Years | M.D. Anderson Cancer Center | |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | NCT01339663 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... aldesleukin autologous tumo... laboratory biom... immunologic tec... immunohistochem... polymerase chai... therapeutic aut... | 18 Years - | Fred Hutchinson Cancer Center | |
| Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | NCT01404702 | Neuroblastoma | Zoledronic Acid Aldesleukin | 2 Years - 21 Years | University of Alabama at Birmingham | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment | NCT00022438 | Melanoma (Skin) | aldesleukin incomplete Freu... recombinant tyr... | 16 Years - | National Cancer Institute (NCI) | |
| Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | NCT01603212 | Melanoma | Vemurafenib IL-2 Interferon Alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML | NCT00871689 | Leukemia | aldesleukin cyclophosphamid... fludarabine pho... umbilical cord ... total-body irra... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00003148 | Leukemia | aldesleukin | 18 Years - 60 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors | NCT00003125 | Breast Cancer Esophageal Canc... Gastric Cancer Lung Cancer Pancreatic Canc... Unspecified Adu... | ALVAC-CEA vacci... aldesleukin sargramostim vaccinia-CEA va... | 18 Years - | Georgetown University | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal | NCT00003229 | Melanoma (Skin) | aldesleukin gp100 antigen tyrosinase pept... | 18 Years - 75 Years | Duke University | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | NCT03190941 | Pancreatic Canc... Gastric Cancer Gastrointestina... Colon Cancer Rectal Cancer | Cyclophosphamid... Fludarabine Anti-KRAS G12V ... Aldesleukin | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | NCT00248430 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... | aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer | NCT00416429 | Kidney Cancer | aldesleukin recombinant int... medroxyprogeste... | 18 Years - | Centre Leon Berard | |
| Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R | NCT00534469 | Leukemia | aldesleukin filgrastim busulfan cytarabine etoposide idarubicin autologous hema... bone marrow tra... peripheral bloo... total-body irra... | 16 Years - 60 Years | City of Hope Medical Center | |
| Immunotherapy for the Treatment of Advanced Solid Tumor | NCT03658785 | Recurrence Tumo... Metastatic Canc... Solid Tumor | TIL Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | Tongji Hospital | |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | NCT00553306 | Recurrent Melan... Stage IV Melano... | therapeutic aut... aldesleukin cyclophosphamid... biopsy immunohistochem... flow cytometry polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma | NCT00250861 | Non-Hodgkin's L... | Rituximab Aldesleukin | 18 Years - | US Oncology Research | |
| Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | NCT01038778 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Aldesleukin Computed Tomogr... Entinostat Fludeoxyglucose... Laboratory Biom... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia | NCT00009698 | Leukemia | aldesleukin | - 21 Years | Children's Oncology Group | |
| IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma | NCT01288963 | Malignant Melan... | IL-2 | 18 Years - | Beth Israel Deaconess Medical Center | |
| Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer | NCT00003181 | Kidney Cancer | aldesleukin sargramostim vinblastine sul... | 18 Years - | National Cancer Institute (NCI) | |
| p53 Vaccine for Ovarian Cancer | NCT00001827 | Ovarian Neoplas... | aldesleukin incomplete Freu... p53 peptide vac... sargramostim therapeutic aut... in vitro-treate... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | NCT00026312 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Aldesleukin Dinutuximab Isotretinoin Laboratory Biom... Pharmacological... Quality-of-Life... Sargramostim | - 30 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Primary or Advanced Glioma | NCT00003067 | Brain and Centr... | aldesleukin lymphokine-acti... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Primary or Advanced Glioma | NCT00003067 | Brain and Centr... | aldesleukin lymphokine-acti... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00054535 | Melanoma (Skin) | aldesleukin recombinant fow... vaccinia-tyrosi... | 16 Years - | National Cancer Institute (NCI) | |
| CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | NCT00924326 | Primary Mediast... Diffuse, Large ... Diffuse Large B... Mantle Cell | Fludarabine Cyclophosphamid... Anti-cluster of... Aldesleukin Fludarabine Cyclophosphamid... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | NCT02489266 | Metastatic Mela... | AKTi-treated TI... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | NCT00706992 | Melanoma | ALVAC-MART-1 va... MART-1:26-35(27... Aldesleukin autologous anti... incomplete Freu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | NCT00004022 | Melanoma (Skin) | aldesleukin autologous tumo... muromonab-CD3 therapeutic aut... surgical proced... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT00005038 | Kidney Cancer | aldesleukin histamine dihyd... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | NCT03197025 | Human Papilloma... HPV-16 High Grade Squa... | Aldesleukin E6 T Cell Recep... | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | NCT00010192 | B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... | rituximab aldesleukin laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | NCT04015336 | Papillomavirus ... Oropharyngeal N... | E7 T-Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | NCT00670748 | Metastatic Mela... Metastatic Rena... Metastatic Canc... | Anti-NY ESO-1 T... aldesleukin Cyclophosphamid... fludarabine pho... ALVAC NY ESO-1 ... | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
